The rising cancer prevalence rate propels the metabolomics market forward. Metabolomics examines potential biomarkers (specific cells, molecules, or genes, gene products, enzymes, or hormones) to aid in early cancer diagnosis. According to the American Cancer Society, lung cancer will be the leading cancer killer in both men and women in the United States in 2020, with 228,820 new cancer cases and 135,720 deaths. Metabolomics techniques such as Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS) have been used to study cancer. Companies such as Metabolon Inc., Bruker Corp., and others have embraced metabolomics as a tool for cancer detection and treatment.
Read More:
https://knackersblogger.blogspot.com/2022/12/metabolomics-market-global-industry.html
